ROVI logo

Laboratorios Farmaceuticos Rovi, S.A. Stock Price

BME:ROVI Community·€3.0b Market Cap
  • 2 Narratives written by author
  • 0 Comments on narratives written by author
  • 47 Fair Values set on narratives written by author

ROVI Share Price Performance

€57.15
-16.45 (-22.35%)
28.0% undervalued intrinsic discount
€79.41
Fair Value
€57.15
-16.45 (-22.35%)
27.6% undervalued intrinsic discount
€78.95
Fair Value
Price €57.15
AnalystConsensusTarget €78.95
kapirey €51.25

ROVI Community Narratives

AnalystConsensusTarget·
Fair Value €79.41 26.0% undervalued intrinsic discount

Expanded CDMO And EU Investments Will Unlock Future Injectables Markets

1users have liked this narrative
0users have commented on this narrative
22users have followed this narrative
kapirey·
Fair Value €51.25 14.7% overvalued intrinsic discount

The future of Rovi is very uncertain, we must wait until the year 2026 to have a clear projection.

1users have liked this narrative
0users have commented on this narrative
5users have followed this narrative

Recent ROVI News & Updates

Laboratorios Farmaceuticos Rovi's (BME:ROVI) Dividend Will Be Reduced To €0.7574

Jun 14
Laboratorios Farmaceuticos Rovi's (BME:ROVI) Dividend Will Be Reduced To €0.7574

Laboratorios Farmaceuticos Rovi's (BME:ROVI) Shareholders Will Receive A Smaller Dividend Than Last Year

May 27
Laboratorios Farmaceuticos Rovi's (BME:ROVI) Shareholders Will Receive A Smaller Dividend Than Last Year

We Think Laboratorios Farmaceuticos Rovi (BME:ROVI) Can Stay On Top Of Its Debt

Feb 09
We Think Laboratorios Farmaceuticos Rovi (BME:ROVI) Can Stay On Top Of Its Debt

Laboratorios Farmaceuticos Rovi, S.A. Key Details

€749.0m

Revenue

€281.6m

Cost of Revenue

€467.4m

Gross Profit

€335.1m

Other Expenses

€132.3m

Earnings

Last Reported Earnings
Jun 30, 2025
Next Reporting Earnings
Nov 06, 2025
Earnings per share (EPS)
2.59
Gross Margin
62.40%
Net Profit Margin
17.66%
Debt/Equity Ratio
22.5%

Laboratorios Farmaceuticos Rovi, S.A. Competitors

 
 
 
 
 
 
 
 
 
 
 
 

Snowflake Analysis

Excellent balance sheet and good value.

0 Risks
3 Rewards

About ROVI

Founded
1946
Employees
2188
CEO
Juan Lopez-Belmonte Encina
WebsiteView website
www.rovi.es

Laboratorios Farmaceuticos Rovi, S.A. manufactures, sells, and markets pharmaceutical products in Spain, European Union, OECD countries, and internationally. The company offers prescription products, including Ameride, Bertanel, Bluxam, Enoxaparin Rovi, Calcium Vitamine D3 Rovi, Exxiv, Prinvil, Rhodogil, Glufan, Hibor, Hirobriz Breezhaler, Neparvis, Medicebran, Medikinet, Mysimba, Orvatez, Tryptizol, Ulunar Breezhaler, and Volutsa. It also provides hospital products, such as Iomeron and Iopamiro, Multihance and Y Prohance, Sonovue, Empowercta+, Empowermr, and CT Express; catheter care under the Fibrilin brand; and Sodium Heparin Rovi. In addition, the company offers contract-manufacturing services comprising compounding, aseptic filling and terminal sterilisation, inspection, installation of safety devices, labelling, packaging, serialisation and aggregation, for different injectable pharmaceutical forms, such as prefilled syringes, vials and cartridges, as well as manufacturing and packaging services for solid products. Its products are used for cardiology, osteoarticular/women’s health, anesthesia /pain, diagnostic imaging contrast agents, central nervous system, urology, endocrinology, respiratory, and primary healthcare areas. The company was incorporated in 1946 and is headquartered in Madrid, Spain. Laboratorios Farmaceúticos Rovi, S.A. is a subsidiary of Norbel Inversiones, S.L.

Market Insight

Q4 2025 is off to a flying start with record highs being printed left, right, and center. US and Japanese stocks made fresh new highs, while the gold price powered through $4,000 for the first time, and Bitcoin crossed the $126k level. Is this all a case of USD weakness, irrational exuberance, or solid fundamentals? This week, we are reviewing Q3 market performance, Q2 earnings season, and the outlook heading into the end of 2025…
Continue reading

Spanish Market Performance

  • 7 Days: 0.3%
  • 3 Months: 9.3%
  • 1 Year: 26.1%
  • Year to Date: 27.2%
The Information Technology sector gained 3.2% while the market remained flat over the last week. More promisingly, the market is up 26% over the past year. Earnings are forecast to grow by 5.1% annually. Market details ›